Heartbeam, Inc. · NASDAQ:BEAT

Heartbeam — Q1 2023 Earnings Presentation

11 slides from Heartbeam's earnings presentation, May 11, 2023

  1. Slide 1: Medical Grade Heart Attack Detection

    Medical Grade Heart Attack Detection Always with the patient First Quarter 2023 Financial Results Conference Call NASDAQ: BEAT May 11, 2023

  2. Slide 2: Disclaimers

    First Quarter 2023 Financial Results Conference Call DISCLAIMERS This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements as to the Company’s future results of operations and financial position

  3. Slide 3: Agenda

    First Quarter 2023 Financial Results Conference Call Agenda • Introduction and Recent Announcements Branislav Vajdic • Strategic Focus and HeartBeam AIMIGo Update Robert Eno • Financing and Financial Results Rick Brounstein • Closing Summary Branislav Vajdic 30 years of experience in 28 years of exp

  4. Slide 4: Key First Quarter 2023 and Subsequent Highlights

    First Quarter 2023 Financial Results Conference Call Key First Quarter 2023 and Subsequent Highlights • Closed a secondary offering and registered direct offering for gross proceeds of $26.5 million to enable company to execute on upcoming clinical, regulatory and commercial milestones, and extend c

  5. Slide 5: Fundraising Activities

    First Quarter 2023 Financial Results Conference Call Fundraising Activities • Closed a secondary offering of $25 million, followed by registered direct offering of $1.5 million for a total of $26.5 million • Oversubscribed from initial $15 million raise • Public Ventures LLC acted as placement agent

  6. Slide 6: 2023 Strategic Focus

    First Quarter 2023 Financial Results Conference Call 2023 Strategic Focus • Immediate focus: obtaining FDA 510(k) clearance for the HeartBeam AIMIGo credit card-sized VECG device, followed by a second FDA clearance on the system’s ability to synthesize an electrocardiogram (ECG). REGULATORY • These

  7. Slide 7: HeartBeam AIMIGo Updates

    First Quarter 2023 Financial Results Conference Call HeartBeam AIMIGo Updates • FDA 510(k) submission for HeartBeam AIMIGo, Version 1 expected in May • Submission is focused on the HeartBeam AIMIGo VECG hardware • Version 2, which includes generation of a synthesized 12L ECG, will be submitted follo

  8. Slide 8: Q1 2023 Financial Highlights

    First Quarter 2023 Financial Results Conference Call Q1 2023 Financial Highlights $ in Thousands Quarters ended March 31, 2023 2022 Operating Expenses: General & Administrative $2,475 $1,414 Research & Development 1,681 734 Total Operating Expenses 4,156 2,148 Loss from Operations (4,156) (2,148) In

  9. Slide 9: Projected Use of Proceeds Into Late 2024

    First Quarter 2023 Financial Results Conference Call Projected Use of Proceeds 2023 In thousands Clinical & Regulatory $2,000 Research & Development $8,000 Product $1,000 General & Administrative $4,000 Into Late 2024 Prepare for Commercialization, Working $9,600 Capital and General Corporate Purpos

  10. Slide 10: Closing Summary

    First Quarter 2023 Financial Results Conference Call Closing Summary • Closed a secondary offering and registered direct offering for gross proceeds of $26.5 million to enable company to execute on upcoming clinical, regulatory and commercial milestones, and extend cash runway into late 2024 • Adjus

  11. Slide 11: Q&A

    Q&A Company Investor Relations Rick Brounstein Chris Tyson Chief Financial Officer Executive Vice President HeartBeam, Inc. MZ North America ir@heartbeam.com Direct: 949-491-8235 BEAT@mzgroup.us www.mzgroup.us www.heartbeam.com 2118 Walsh Avenue, Suite 210 Santa Clara, CA 95050

Heartbeam — Q1 2023 Earnings Presentation on 6ix